News | Heart Failure | September 18, 2019

FDA Grants Fast Track Designation for Farxiga in Heart Failure

FDA approves accelerated development for dapagliflozin for adults with heart failure with reduced ejection fraction or preserved ejection fraction

FDA Grants Fast Track Designation for Farxiga in Heart Failure

September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure. The designation applies to adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

The FDA’s Fast Track program is designed to accelerate the development and review of new medicines for the treatment of serious conditions where there is an unmet treatment need.

The Fast Track designation is based on two Phase III trials, DAPA-HF and DELIVER, which investigated the role of FARXIGA in patients with heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively. The results of DAPA-HF, presented at the 2019 European Society of Cardiology (ESC) Congress, Aug. 31-Sept. 4 in Paris, France, showed Farxiga reduced the composite of CV death or worsening of heart failure by 26 percent (p<0.0001) and showed a reduction in each of the individual components of the composite endpoint.

Farxiga is currently approved as a monotherapy and as part of combination therapy to improve glycemic control in adults with type 2 diabetes (T2D). In August 2019 the FDA granted Fast Track designation for the development of Farxiga to delay the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease. Farxiga is not indicated to reduce the risk of HF, CV death or kidney disease.

Read the article “Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure”

FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations — October 2019 update

For more information: www.escardio.org

Related Content

ESC President Barbara Casadei, M.D., DPhil, FRCP, FESC, a British Heart Foundation Professor and an honorary consultant cardiologist at the John Radcliffe Hospital in Oxford, speaks at a press conference at the 2019 ESC Congress. #ESC19 #ESC2019

ESC President Barbara Casadei, M.D., DPhil, FRCP, FESC, a British Heart Foundation Professor and an honorary consultant cardiologist at the John Radcliffe Hospital in Oxford, speaks at a press conference at the 2019 ESC Congress.

 

Feature | ESC | September 09, 2019
September 9, 2019 — More than 33,000 health professionals gathered over five days to attend the 2019...
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC | September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC | September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
Giving oxygen to patients suffering a heart attack is not beneficial, according to the DETO2X-AMI study.

Giving oxygen to patients suffering a heart attack is not beneficial, according to the DETO2X-AMI study presented at ESC 2017.

Feature | ESC | September 07, 2017
September 7, 2017 — Oxygen therapy does not improve survival in patients with heart attack symptoms, according to lat
PURE study may cause revision of fat intake guidelines for cardiology.
Feature | ESC | September 07, 2017
September 7, 2017 — Researchers at the European Society of Cardiology (ESC) Congress called for a reconsideration of
Overlay Init